Original Query: ALL
Previous Study | Return to List | Next Study

NEBIDO in Symptomatic Late Onset Hypogonadism (SLOH)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01092858
Recruitment Status : Terminated
First Posted : March 25, 2010
Last Update Posted : November 5, 2014
Information provided by (Responsible Party):

Brief Summary:
The design of the study is a standard double-blind design, which is needed in this study to allow for unbiased evaluation of efficacy and safety. The effect of the additional impact of testosterone replacement therapy in hypogonadal men on muscle strength and quality of life in comparison to physical exercise alone will be assessed. Treatment duration will be 54 weeks, to monitor the increase as well as the "steady state" of the parameters assessed.

Condition or disease Intervention/treatment Phase
Hypogonadism Drug: Testosterone Undeconate (Nebido, BAY86-5037) Drug: Placebo Phase 4

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 4 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Effect of Exercise Alone or in Combination With Testosterone Replacement on Muscle Strength and Quality of Life in Older Men With Low Testosterone Concentrations: a Randomized Double-blind, Placebo Controlled Study
Study Start Date : September 2010
Primary Completion Date : July 2011
Study Completion Date : July 2011

Arm Intervention/treatment
Experimental: Arm 1 Drug: Testosterone Undeconate (Nebido, BAY86-5037)
Testosterone undecanoate 1000 mg (4 ml) i.m. injection at baseline, at week 6, at week 18, at week 30 and at week 42, respectively
Placebo Comparator: Arm 2 Drug: Placebo
Matching placebo i.m. injections at baseline, at week 6, at week 18 at week 30 and at week 42, respectively

Primary Outcome Measures :
  1. Dynamic maximum strength -one repetition maximum (1-RM ) - of upper and lower extremity after 54 weeks [ Time Frame: At baseline, at week 54 ]

Secondary Outcome Measures :
  1. Isometric maximum strength [ Time Frame: At baseline, at week 54 ]
  2. Grip strength [ Time Frame: At baseline, at week 54 ]
  3. Chair raising test [ Time Frame: At baseline, at week 54 ]
  4. Arm curl test [ Time Frame: At baseline, at week 54 ]
  5. Bicycle stress test with spirometry [ Time Frame: At baseline, at week 54 ]
  6. SF-36 Questionnaire [ Time Frame: At baseline, at week 54 ]
  7. AMS-Questionnaire [ Time Frame: At baseline, at week 54 ]
  8. FINGER Questionnaire [ Time Frame: At baseline, at week 54 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   60 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Men aged 60 years and older (>60yrs), untrained
  • Symptomatic hypogonadism as defined by a) and b)
  • a) Total testosterone below 12 nmol/l (measurement 7.00-11.00 a.m.)
  • b)Total Aging Males' symptom score above 36
  • Willing to avoid significant change in the pattern of physical exercise and lifestyle for the duration of the study
  • Residence in Cologne Area

Exclusion Criteria:

  • Previous assignment to treatment during this study
  • Use of androgen therapy or anabolic steroids respectively 12 months of entry into the study (i.e. screening visit/visit 1)
  • Current participation in an exercise program or within the last 6 months
  • Suspicion or known history of prostate or breast cancer or other hormone dependent neoplasia
  • Abnormal finding on Digital Rectal Examination (DRE)
  • Prostate specific antigen (PSA) level >4 ng/ml
  • History of clinically significant post void residual urine (> 150 ml)
  • Suspicion or known history of liver tumor
  • Hypersensitivity to the active substances or any of the excipients of NEBIDO e.g. benzyl-benzoate and castor oil
  • Blood coagulation irregularities presenting an increased risk of bleeding after intramuscular injections including vitamin-K-antagonists or other strong anticoagulants
  • 32 Additional Exclusion Criteria

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01092858

Köln, Nordrhein-Westfalen, Germany, 50931
Sponsors and Collaborators
Study Director: Bayer Study Director Bayer

Additional Information:
Responsible Party: Bayer Identifier: NCT01092858     History of Changes
Other Study ID Numbers: 14853
2009-017139-16 ( EudraCT Number )
First Posted: March 25, 2010    Key Record Dates
Last Update Posted: November 5, 2014
Last Verified: November 2014

Keywords provided by Bayer:
Testosterone undecanoate

Additional relevant MeSH terms:
Gonadal Disorders
Endocrine System Diseases
Testosterone enanthate
Testosterone undecanoate
Testosterone 17 beta-cypionate
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Anabolic Agents